COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.

Also called NCT02404376

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 378 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02404376
Other papers using this trial's data
  • Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk Scientific reports, 2023-04-27 DOI, PubMed 37106099, PMC10140265 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02404376. Randomized; double masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2019-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
Acronym
COMBAT-MI
Condition
ST Elevation Acute Myocardial Infarction
Intervention (Drug)
Exenatide
Intervention (Other)
Remote Ischemic Conditioning (RIC)
Intervention (Drug)
Placebo
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute (class: other)

Record details

Record id
cardio:ct-nct02404376
Content hash
5b4359f385e0612979295b85d7af429befcf6a0f17a5f9eae41f12d4bef4a7a7